AstraZeneca Pharma India Limited — Important, 30-05-2025: Updates

AstraZeneca Pharma India posted 32% revenue growth, exceeding INR 1716.3 Cr in FY 2024-25, fueled by Oncology (INR 1117.1 Cr) and Biopharmaceuticals (INR 488.1 Cr). Key product launches include Palivizumab (RSV prevention), Tremelimumab and Durvalumab (liver and lung cancers), and a new COPD treatment. Expanded indications for oncology and rare diseases broaden market reach. Strengthened leadership across commercial and medical teams supports growth. Multiple industry awards highlight the company’s innovation and strong position in India’s specialized pharma sector.